Drug: Selzentry (maraviroc)
Approval Date: August 6, 2007
Scoop: Selzentry is a CCR5 antagonist, which prevents the virus from entering white blood cells. The process reduces viral load and boosts T-cell count. For Pfizer, it was a much-needed win on the regulatory side after a series of disappointing setbacks in its pipeline development program.